Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
The company was founded in 2021 and is headquartered in Zug, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 25 | -0.63 Decreased by -186.36% | -0.74 Increased by +14.34% |
| Feb 26, 25 | -0.72 Decreased by -500.00% | -0.59 Decreased by -21.46% |
| Nov 12, 24 | -0.56 Decreased by -211.11% | -0.44 Decreased by -27.27% |
| Aug 7, 24 | -0.39 Decreased by -69.57% | -0.28 Decreased by -39.29% |
| May 7, 24 | -0.22 Increased by +4.35% | -0.19 Decreased by -15.79% |
| Feb 29, 24 | -0.12 Increased by +61.29% | -0.23 Increased by +47.83% |
| Nov 14, 23 | -0.18 Increased by +33.33% | -0.23 Increased by +21.74% |
| Aug 10, 23 | -0.23 Increased by +32.35% | -0.27 Increased by +14.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 101.85 K Increased by +416.01% | -45.60 M Decreased by -513.20% | Decreased by -44.78 K% Decreased by -18.84% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -35.39 M Decreased by -275.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -24.27 M Decreased by -139.34% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 19.74 K Increased by +N/A% | -13.67 M Decreased by -11.90% | Decreased by -69.28 K% Decreased by N/A% |
| Dec 31, 23 | 19.74 K Increased by +N/A% | -7.44 M Decreased by -284.32% | Decreased by -37.68 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.43 M Increased by +36.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -10.14 M Increased by +41.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.22 M Increased by +23.05% | Decreased by N/A% Decreased by N/A% |